Mufg Securities Americas Inc. Purchases New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Mufg Securities Americas Inc. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,397 shares of the biopharmaceutical company's stock, valued at approximately $1,699,000.

Several other institutional investors have also recently bought and sold shares of the business. Matrix Trust Co raised its holdings in shares of Gilead Sciences by 515.2% in the fourth quarter. Matrix Trust Co now owns 1,052 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 881 shares during the last quarter. Wedmont Private Capital raised its holdings in shares of Gilead Sciences by 41.2% in the fourth quarter. Wedmont Private Capital now owns 13,481 shares of the biopharmaceutical company's stock valued at $1,212,000 after purchasing an additional 3,931 shares during the last quarter. Pallas Capital Advisors LLC raised its holdings in shares of Gilead Sciences by 4.0% in the fourth quarter. Pallas Capital Advisors LLC now owns 8,150 shares of the biopharmaceutical company's stock valued at $753,000 after purchasing an additional 314 shares during the last quarter. First Financial Corp IN purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $68,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $471,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. This represents a 9.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 25,429 shares of company stock valued at $2,894,445. Corporate insiders own 0.27% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Morgan Stanley raised their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a report on Thursday, February 13th. Finally, Bank of America raised their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Price Performance

NASDAQ:GILD traded up $3.08 during mid-day trading on Monday, hitting $105.58. 3,574,575 shares of the stock traded hands, compared to its average volume of 7,661,642. The business's 50-day moving average price is $105.75 and its 200 day moving average price is $99.84. The company has a market cap of $131.34 billion, a PE ratio of 285.50, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.32) earnings per share. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.99%. Gilead Sciences's dividend payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.